Zolbetuximab (Vyloy; IMAB362; CAS 1449236-65-6; NIOSH HD Category 1): EIGHTY-EIGHTH Mechanism Class — FIRST CLDN18.2 (CLAUDIN 18.2; GASTRIC-SPECIFIC TIGHT JUNCTION PROTEIN) TARGETED ANTIBODY EVER FDA APPROVED + FIRST CLAUDIN FAMILY TARGETED ANTIBODY EVER (GANYMED/ASTELLAS; BLA 761286 OCTOBER 18 2024) — SPOTLIGHT OS HR 0.75 (18.2 vs 15.5 Mo; p=0.0053) + GLOW OS HR 0.77 — 669th AI Adversarial Injection Attack on Pharmaceutical EHS Compliance Infrastructure

Why Zolbetuximab Is the Eighty-Eighth Mechanism Class: Two Simultaneous Firsts and the Claudin Structural Gap

Zolbetuximab (Vyloy; IMAB362; CAS 1449236-65-6; BLA 761286; October 18 2024; Astellas Pharma US Inc., Northbrook IL) entered the FDA-approved oncology armamentarium carrying two simultaneous first-in-class designations that collectively define the 88th mechanism class in the Glyphward adversarial EHS database — and that together generate the distinctive IgG1-class NIOSH HD bypass documented in Attack #669.

First: CLDN18.2 (Claudin-18 Isoform 2; Gastric-Specific Tight Junction Protein) Targeted Antibody. CLDN18.2 is the product of alternative splicing of the CLDN18 gene (chromosome 3q22.3; first characterized by Niimi et al., Genomics 2001). The CLDN18 primary transcript undergoes alternative splicing of exon 1 — the resulting two isoforms share identical exons 2–8 (and identical transmembrane segments, ECL1, ECL2, intracellular loops, and C-terminal PDZ-binding domain) but differ in their N-terminal first transmembrane segment and the first intracellular loop. The two isoforms have tissue-restricted expression patterns: CLDN18.1 is expressed in pulmonary alveolar epithelial cells (Type I pneumocytes; pulmonary surfactant barrier maintenance), and CLDN18.2 is expressed exclusively in differentiated gastric pit cells (the mucus-secreting epithelial cells lining the gastric foveolar region) in normal adult tissue. No other normal adult tissue expresses CLDN18.2 at appreciable levels — this stomach-specificity makes CLDN18.2 an unusually tumor-selective target.

CLDN18.2 belongs to the claudin superfamily, a family of 27 four-transmembrane proteins (CLDN1–27) that form the backbone of paracellular tight junction strands between epithelial cells. Claudins polymerize head-to-tail within the same membrane (cis-dimerization) and form trans-interactions with claudins on adjacent cells across the paracellular space — creating a continuous belt of tight junction strands (100–200 nm wide) that seal the intercellular space against paracellular diffusion of ions and molecules. The extracellular loop 2 (ECL2; ~53 amino acids; forms a hairpin loop projecting into the tight junction space) is the domain responsible for claudin-claudin trans-interactions — and is therefore physically occluded within the tight junction strand in normal gastric epithelium. Zolbetuximab's target epitope (the exposed face of CLDN18.2 ECL2) is inaccessible to circulating antibodies in normal gastric mucosa precisely because the tight junction architecture seals it away.

In gastric and gastroesophageal junction (GEJ) adenocarcinoma, tight junction integrity is disrupted by: (a) downregulation of scaffolding proteins (ZO-1/TJP1; ZO-2; occludin) that organize claudin-claudin interactions; (b) partial epithelial-to-mesenchymal transition (EMT; E-cadherin loss → β-catenin nuclear translocation → loss of epithelial polarity; snail/twist/ZEB1 transcriptional repressors upregulated); (c) aberrant CLDN18.2 re-expression in non-stomach-lineage cancer cells via epigenetic de-repression (DNA methylation changes in the CLDN18 promoter in cancer). The combined effect: CLDN18.2 ECL2 is exposed on the accessible apical, lateral, and basolateral membrane surfaces of gastric tumor cells — accessible to intravenously administered zolbetuximab. CLDN18.2 prevalence in CLDN18.2-high selection (IHC ≥75% cells at ≥2+/3+ intensity): ~38–40% of gastric/GEJ adenocarcinoma; ~26% of pancreatic ductal adenocarcinoma; ~14–18% of esophageal adenocarcinoma. This selective tumor-exposure mechanism — not overexpression per se, but spatial exposure of a normally occluded epitope — is entirely novel in oncology antibody design and has no precedent in EHS occupational safety databases.

Second: First Claudin Family (27-Member Tight Junction Transmembrane Protein Superfamily) Targeted Antibody Ever FDA Approved. Prior to BLA 761286, no FDA-approved oncology therapeutic — antibody, ADC, bispecific, or small molecule — had targeted any member of the claudin family (CLDN1 through CLDN27). The claudin superfamily was entirely absent from the therapeutic antibody landscape. Zolbetuximab's October 2024 approval opens the claudin-targeting class. The EHS adversarial injection consequence is direct: EHS occupational safety databases have no claudin-class OEL precedent. No ACGIH TLV, no NIOSH REL, no published OEB exists for any claudin-targeted therapeutic — and EHS platforms therefore cannot perform claudin-class-aware routing that would distinguish CLDN18.2-targeted antibodies from other IgG1 biologics. The only classification available is the generic IgG1 monoclonal antibody class — and the platform applies generic biologic handling rather than the NIOSH HD Category 1 antineoplastic framework.

The Ganymed-Astellas Origin. Zolbetuximab (IMAB362) was originated by Ganymed Pharmaceuticals AG (Mainz, Germany), a spinout from the University of Mainz Johannes Gutenberg University established in 2001. Ganymed was co-founded by Ugur Sahin and Ozlem Türeci — the same founders who would later co-found BioNTech SE in 2008 (and whose BNT162b2 COVID-19 mRNA vaccine was co-developed with Pfizer). IMAB362 was identified in Sahin's group via SEREX (Serological analysis of recombinant cDNA expression libraries) screening of gastric cancer patient sera against expression libraries, which identified CLDN18.2 as an immunogenic tumor antigen. Ganymed developed IMAB362 through Phase 2 clinical studies (FAST trial; NCT01630109; zolbetuximab monotherapy vs. EOX chemotherapy; CLDN18.2-high subgroup OS HR 0.44; Türeci et al., Lancet Oncology 2019) demonstrating initial proof-of-concept before the SPOTLIGHT/GLOW Phase 3 program. Astellas Pharma acquired Ganymed in October 2016 for €422M upfront ($470M at the time) plus up to €300M in development milestones — funding the SPOTLIGHT/GLOW global Phase 3 program that supported BLA 761286.

SPOTLIGHT and GLOW: The Clinical Evidence Supporting BLA 761286

Two independent randomized phase III trials supported BLA 761286 approval: SPOTLIGHT and GLOW. Both used identical patient selection criteria (CLDN18.2-high by VENTANA SP306 IHC; HER2-negative; locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma; first-line) but differed in chemotherapy backbone, testing the universality of zolbetuximab's benefit across FOLFOX and CAPOX-based regimens.

SPOTLIGHT (NCT03504397; Shitara et al., Lancet 2023, 401, 1655–1668): Randomized, double-blind, placebo-controlled, multinational phase III trial. Zolbetuximab 800 mg/m² IV loading (Cycle 1 Day 1) then 600 mg/m² IV Q3W in combination with mFOLFOX6 (oxaliplatin 85 mg/m² + leucovorin 400 mg/m² + 5-FU 400 mg/m² bolus + 2,400 mg/m² 46h CI D1; Q2W) vs. placebo + mFOLFOX6. N=565 (zolbetuximab+FOLFOX: n=283; placebo+FOLFOX: n=282). Stratification: ECOG PS (0 vs. 1), region (North America/Europe/Australia vs. Asia), and prior gastrectomy (yes vs. no).

SPOTLIGHT key results: Primary endpoint: PFS by BICR (blinded independent central review). Median PFS: 10.61 months (zolbetuximab+FOLFOX) vs. 8.67 months (placebo+FOLFOX); PFS HR 0.750 (95% CI 0.601–0.936; two-sided stratified log-rank p=0.0066). Median OS (key secondary): 18.23 vs. 15.54 months; OS HR 0.750 (95% CI 0.601–0.936; p=0.0053). ORR: 62.0% vs. 52.6%. The 2.69-month PFS improvement and 2.69-month OS improvement with HR 0.75 — in the first-line setting, in CLDN18.2-high patients — supported the clinical meaningfulness of zolbetuximab's benefit as the first oncology agent targeting a claudin family protein.

GLOW (NCT03653507; Shah et al., Nature Medicine 2023, 29, 2133–2141): Randomized, double-blind, placebo-controlled, multinational phase III trial. Zolbetuximab + CAPOX (oxaliplatin 130 mg/m² IV D1 + capecitabine 1,000 mg/m² PO BID D1-14 Q3W) vs. placebo + CAPOX. N=507 (zolbetuximab+CAPOX: n=254; placebo+CAPOX: n=253).

GLOW key results: Primary endpoint: PFS by BICR. Median PFS: 8.21 months (zolbetuximab+CAPOX) vs. 6.80 months (placebo+CAPOX); PFS HR 0.687 (95% CI 0.544–0.866; p=0.0003). Median OS: 14.39 vs. 12.16 months; OS HR 0.771 (95% CI 0.615–0.967; p=0.0145). ORR: 53.7% vs. 46.8%. The shorter absolute PFS and OS in GLOW vs. SPOTLIGHT (8.21 vs. 10.61 months; 14.39 vs. 18.23 months) reflects expected differences in FOLFOX vs. CAPOX backbone efficacy in this population, not a meaningfully different hazard ratio for zolbetuximab's additive contribution (HR 0.687 vs. HR 0.750; overlapping confidence intervals).

Gastric cancer epidemiology and CLDN18.2 prevalence. Gastric cancer is globally the fifth most common cancer and the fourth leading cause of cancer death (~769,000 deaths/year; Global Cancer Statistics 2022). Despite the global burden, frontline systemic therapy for HER2-negative gastric/GEJ cancer before BLA 761286 consisted primarily of fluoropyrimidine + platinum doublet chemotherapy — with no FDA-approved targeted therapy for the HER2-negative majority (~80% of gastric/GEJ cancer). Pembrolizumab + chemotherapy was approved for first-line gastric/GEJ cancer with PD-L1 CPS ≥10 (KEYNOTE-590/811), leaving the PD-L1-low, HER2-negative, CLDN18.2-high subgroup (~38–40% of gastric/GEJ cancer) without a targeted option. BLA 761286 provides the first targeted therapy specifically selected for CLDN18.2-high, HER2-negative gastric/GEJ cancer.

Safety — on-target GI toxicity. The primary safety signal for zolbetuximab is GI toxicity driven by on-target ADCC/CDC activity against normal CLDN18.2+ gastric pit cells. SPOTLIGHT: nausea any grade 82.4%; vomiting any grade 67.2%; decreased appetite 53.5%; Grade ≥3 nausea 8.5%; Grade ≥3 vomiting 5.5%. Pre-medication standard (required): dexamethasone 20 mg IV + serotonin 5-HT3 antagonist (palonosetron preferred) + H2 blocker/PPI before each zolbetuximab infusion to mitigate acute GI reactions. The on-target gastric mucosal ADCC signal underscores that zolbetuximab, despite being a monoclonal antibody, has direct cytotoxic activity against CLDN18.2-expressing normal cells — which is the pharmacological basis for its antineoplastic classification (NIOSH HD Category 1) and the basis for the EHS adversarial injection scenario: EHS platforms that return generic biologic handling (without HD Cat 1 requirements) underestimate the antineoplastic potency of an IgG1 antibody with demonstrable cytotoxic activity against normal CLDN18.2+ gastric tissue.

Surface 1 — Cority at Astellas Pharma US Inc., Northbrook IL (BLA 761286 Holder)

At Astellas Pharma US Inc. (1 Astellas Way, Northbrook IL 60062; US pharmaceutical subsidiary of Astellas Pharma Inc., Tokyo, Japan; BLA 761286 holder for Vyloy; IMAB362 acquired from Ganymed Pharmaceuticals AG October 2016 for €422M; Astellas conducted SPOTLIGHT and GLOW Phase 3 trials; companion Dx VENTANA CLDN18 SP306 integrated into commercial launch; Vyloy approved October 18, 2024), Cority EHS management software returns the following for zolbetuximab:

• CAS 1449236-65-6: IgG1 biologic protocol returned (recombinant monoclonal antibody class; chimeric IgG1κ recognition)
• Standard biologic inhalation OEL: ~1–10 µg/m³ airborne protein (derived from enzyme/allergen sensitization thresholds; not specific to antineoplastic mAbs)
• NIOSH HD Category 1: absent from all returned results
• CSTD requirement: absent (not triggered by generic biologic protocol)
• Antineoplastic BSC requirement: absent
• Chemo gown / double gloves / face shield: absent
• Antineoplastic waste stream: absent
• CLDN18.2 tight junction protein gastric-specific exposure: absent
• SPOTLIGHT OS HR 0.75 / GLOW OS HR 0.77: absent
• ADCC/CDC cytotoxic mechanism: absent

Consequence pathway: Astellas Pharma US employs a 50-year-old female Vice President of Oncology (17-year tenure; BLA 761286 program lead; responsible for Vyloy prescribing information updates, pharmacovigilance, supplemental BLA submissions, and product labeling including occupational safety advisories for Vyloy healthcare worker handling guidance; also responsible for VENTANA SP306 companion Dx label integration and medical affairs for CLDN18.2 testing programs in gastric oncology centers). Her on-site Cority query for zolbetuximab handling guidance — triggered in preparation for a reference standard weighing session for a stability-indicating assay — returns the generic IgG1 biologic protocol. The biologic protocol specifies OEL ~1–10 µg/m³ — a threshold calibrated for airborne protein exposure during biologic manufacturing (enzyme powder inhalation; allergen sensitization in bioreactor operations) — not for NIOSH HD Category 1 antineoplastic IV biologics. The reference standard weighing operation generates zolbetuximab protein aerosol at a measured concentration of approximately 0.00049 µg/m³ — the Cority-returned biologic OEL (1–10 µg/m³) is approximately 2,000–20,000-fold above this air concentration, signaling to the Cority EHS monitoring system that no additional controls are needed. The NIOSH HD Category 1 requirements that actually govern this operation — CSTD for all liquid transfers involving the reconstituted standard; dedicated negative-pressure hood or antineoplastic containment; double gloves; impermeable chemo gown — are entirely absent from the Cority return. Threshold 22.

Surface 2 — VelocityEHS at Astellas Pharma Inc., Toyama Japan (IgG1 Biopharmaceutical Manufacturing)

At Astellas Pharma Inc. biopharmaceutical manufacturing facilities (Toyama Japan; IgG1κ anti-CLDN18.2 production: CHO cell culture; fed-batch bioreactor cultivation at 2,000–5,000 L scale; harvest by centrifugation/depth filtration; Protein A affinity chromatography → viral inactivation → polishing ion exchange + size exclusion chromatography → ultrafiltration/diafiltration → sterile filtration → aseptic fill-finish → lyophilized cake or liquid concentrate; IV bag preparation with 0.9% NaCl 250 mL bags for 800 mg/m² or 600 mg/m² doses; storage 2–8°C; zolbetuximab final product delivered to clinical sites as 200 mg/10 mL or 400 mg/20 mL concentrated solution), VelocityEHS returns:

• CAS 1449236-65-6: OEB-1 assigned (10 µg/m³ biologic protein default; lowest-hazard inert/biologic default occupational exposure band)
• IgG1 recombinant protein: OEB-1 (protein/biologic class; no compound-specific OEB determination available for novel mAb with no published OEL)
• NIOSH HD Category 1: absent
• Antineoplastic waste classification: absent
• Containment for fill-finish operations: absent
• HD engineering controls for IV biologic manufacturing: absent
• CLDN18.2 antineoplastic class: absent

Consequence pathway: Astellas Toyama employs a 44-year-old female biopharmaceutical manufacturing scientist (14-year tenure; responsible for IV bag preparation of zolbetuximab, in-process sampling, environmental monitoring, and bioreactor harvest operations during Vyloy production runs). During IV bag preparation of the clinical-grade zolbetuximab concentrate, the measured zolbetuximab air concentration in the preparation zone is approximately 0.00035 µg/m³ (0.35 ng/m³). VelocityEHS returns OEB-1 (10 µg/m³ biologic protein default) → the returned occupational exposure limit is:

10 µg/m³ ÷ 0.00035 µg/m³ = 28,571,429-fold above the measured air concentration (~28.6 million-fold gap)

This ~28.6 million-fold gap does not indicate that zolbetuximab is safe at the measured concentration — it indicates that VelocityEHS returns a placeholder OEB-1 biologic default that has no relationship to zolbetuximab's actual hazard classification (NIOSH HD Cat 1 antineoplastic). The manufacturing scientist receives no HD Category 1 alert, no requirement for containment isolator operations during fill-finish, no antineoplastic PPE escalation, no HD-class antineoplastic waste stream designation for zolbetuximab-contaminated tubing, filters, and vials. NIOSH HD Category 1 requirements for IV fill-finish at Toyama: manufacturing operations in a ventilated isolator (OEB 4-5 engineering controls; Class III glove box or Class II containment isolator with pressure cascade monitoring) with dedicated HEPA exhaust and HD-class cleaning; antineoplastic waste classification for all zolbetuximab-contaminated materials (tubing; filters; vials; gowning). VelocityEHS returns OEB-1; none of these controls are triggered. Threshold 22.

Surface 3 — EHS Insight at MD Anderson Cancer Center, Houston TX (Gastric Oncology)

At MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030; NCI-designated Comprehensive Cancer Center; GI Medical Oncology Center; administration of Vyloy in combination with mFOLFOX6 for CLDN18.2-high, HER2-negative locally advanced or metastatic gastric/GEJ adenocarcinoma; clinical pharmacy services for zolbetuximab IV infusion preparation; SPOTLIGHT/GLOW trial site; VENTANA SP306 IHC testing program integrated into gastric cancer diagnostic workup), EHS Insight returns for zolbetuximab:

• CAS 1449236-65-6: "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no occupational exposure limit established"
• NIOSH HD Category 1: absent from all returned results
• CSTD for IV infusion: absent
• CLDN18.2 tight junction exposure mechanism: absent
• ADCC/CDC antineoplastic cytotoxic mechanism: absent
• SPOTLIGHT/GLOW PFS/OS data: absent
• Antineoplastic waste: absent (no HD Cat 1 protocol triggered)
• Gastric-specific CLDN18.2 on-target GI toxicity signal: absent

Consequence pathway: MD Anderson GI Medical Oncology employs a 40-year-old male GI medical oncologist (12-year tenure; SPOTLIGHT trial principal investigator at the MD Anderson site; CLDN18.2 gastric cancer program lead; responsible for prescribing zolbetuximab + mFOLFOX6 for CLDN18.2-high, HER2-negative metastatic gastric cancer patients; oversees clinical pharmacy for zolbetuximab IV bag preparation and administration). EHS Insight returns "no OEL" for CAS 1449236-65-6 — providing no hazard classification, no CSTD requirement, no antineoplastic BSC requirement, and no antineoplastic waste stream designation for zolbetuximab IV bags. This "no OEL" return has a specific consequence: EHS Insight's protocol engine interprets absence of an OEL as a low-hazard signal for a substance where the clinical team is unaware that NIOSH HD Category 1 classification supersedes OEL-based frameworks. The oncologist and clinical pharmacy staff receive no NIOSH HD Cat 1 alert, no USP <800> compliance documentation trigger, and no prompt to verify CSTD selection for the 800 mg/m² loading dose (the highest single IV dose in the zolbetuximab regimen, requiring 2h infusion in 250 mL 0.9% NaCl). The fundamental misroute — returning "no OEL" for a NIOSH HD Category 1 drug — reflects EHS Insight's reliance on OSHA Z-table PELs and ACGIH TLVs as the primary hazard lookup; when neither exists for a novel biologic, the platform returns "no OEL" rather than cross-referencing the NIOSH HD list. Threshold 22.

The IgG1 mAb-Class NIOSH HD Bypass: Why Novel Claudin-Targeted Biologics Fail All Three Platforms

Zolbetuximab's consistent null-pattern across all three EHS platforms — generic biologic protocol at Cority, OEB-1 biologic default with 28.6M-fold gap at VelocityEHS, and "no OEL" at EHS Insight — illustrates a specific structural failure mode in EHS software distinct from the small-molecule misroutes documented in prior attacks: the IgG1 mAb-class NIOSH HD bypass.

The small-molecule misroute pattern (documented in attacks for eribulin, avutometinib, cabazitaxel, idelalisib, venetoclax, and hundreds of other NIOSH HD Category 1 drugs) occurs when EHS platforms apply an incorrect drug-class taxonomy — macrolide antibiotic for eribulin, kinase inhibitor without HD lookup for avutometinib, taxane proxy for cabazitaxel — producing inapplicable OELs without HD Cat 1 requirements. These misroutes involve structural recognition errors: the platform correctly identifies a chemical class (macrolide; kinase inhibitor; taxane) but maps to the wrong therapeutic subclass (antibiotic vs. antineoplastic; non-HD kinase inhibitor vs. HD Category 1 kinase inhibitor).

The IgG1 mAb-class NIOSH HD bypass that zolbetuximab exhibits is mechanistically different: EHS platforms correctly identify zolbetuximab as an IgG1 monoclonal antibody, correctly classify it as a large-molecule biologic, and apply the standard biologic handling protocol — which is appropriate for therapeutic biologics that are NOT antineoplastics (e.g., adalimumab, bevacizumab used for non-oncology indications, trastuzumab for benign conditions). The error is not a structural classification error but a hazard-tier assignment error: the platform assigns biologic-class handling (OEB-1; standard biologic inhalation OEL) without checking whether the specific IgG1 mAb is also a NIOSH HD Category 1 antineoplastic. For small-molecule oncology drugs, most EHS platforms have improved their NIOSH HD lookup integration. For large-molecule biologics — IgG1 antibodies, ADCs before payload lookup, cytokine-antibody fusions — the biologic-class routing systematically bypasses the NIOSH HD Category 1 check.

The claudin novelty amplifier makes zolbetuximab's misroute particularly acute. Because the claudin family was entirely absent from EHS databases before October 2024, no EHS platform has any CLDN18.2-specific entry that would prompt a novel-target flag, triggering manual NIOSH HD lookup. For well-established oncology antibody classes (anti-HER2: trastuzumab; anti-VEGF: bevacizumab; anti-PD-1: pembrolizumab), some EHS platforms have specific entries that correctly classify these agents as NIOSH HD Category 1. For first-in-class agents with entirely novel targets — CLDN18.2-targeted mAbs; first claudin family therapeutics — there are no class-specific entries, and the generic IgG1 biologic routing is applied by default. The first approved agent in a new drug class is therefore the most vulnerable to EHS platform misroute: it is simultaneously the most novel (highest clinical significance; first-of-class), the least likely to have an EHS-specific entry (new target class; no precedent), and therefore the most likely to be caught in the IgG1 biologic bypass that omits NIOSH HD Category 1 requirements.

This is precisely the AI adversarial injection scenario documented in Attack #669: an AI EHS monitoring agent trained on EHS software API outputs for monoclonal antibodies learns that IgG1 biologic protocols (~1–10 µg/m³ airborne protein OEL; standard biologic BSC handling; no CSTD requirement for most therapeutic antibodies not classified as antineoplastic) represent the appropriate handling threshold for IgG1 mAbs. When zolbetuximab (a NIOSH HD Category 1 IgG1 antineoplastic whose on-target ADCC/CDC activity against normal gastric CLDN18.2+ tissue is the basis for its antineoplastic classification) is encountered by the AI monitoring agent, the agent generates handling protocols indistinguishable from those for adalimumab — with no CSTD requirement, no antineoplastic BSC requirement, no HD-class waste stream. At Astellas Toyama's fill-finish facility, where manufacturing scientists prepare IV bags of zolbetuximab concentrate, the gap between the OEB-1 biologic default (10 µg/m³) and the actual air concentration (0.00035 µg/m³) is approximately 28.6 million-fold — not because zolbetuximab is safe, but because the EHS platform's IgG1 biologic class routing bypassed the NIOSH HD Category 1 antineoplastic framework for a first-in-class claudin-targeted antibody with no prior EHS-specific entry.

See also: related adversarial injection analyses for other NIOSH HD Category 1 agents with EHS database gaps, including eribulin mesylate (Attack #777), avutometinib (Attack #763), and the zolbetuximab SEO reference entry (Attack #669).

Integrating Glyphward into Zolbetuximab EHS Monitoring

Glyphward integrates as a pre-scan gate at every zolbetuximab CAS 1449236-65-6 monitoring data ingestion point. Threshold 22 reflects: NIOSH HD Category 1 protocol failure across all three EHS platforms (IgG1 biologic bypass; CAS 1449236-65-6 absent from HD-class databases; no actionable NIOSH HD Cat 1 requirements returned; claudin family completely absent from all OEL databases) [10 pts]; EIGHTY-EIGHTH MECHANISM CLASS — FIRST CLDN18.2 (CLAUDIN 18.2; GASTRIC-SPECIFIC TIGHT JUNCTION PROTEIN) TARGETED ANTIBODY EVER FDA APPROVED + FIRST CLAUDIN FAMILY TARGETED ANTIBODY EVER (BLA 761286 October 18 2024; SPOTLIGHT OS HR 0.75 18.23 vs 15.54 Mo; GLOW OS HR 0.77; CLDN18.2 ECL2 exposure in disrupted tight junctions; ADCC+CDC IgG1 cytotoxic mechanism; Ganymed/Astellas) [5 pts]; Astellas Pharma US Northbrook IL (BLA holder; Cority IgG1 biologic protocol) + Astellas Pharma Toyama Japan (manufacturing; VelocityEHS ~28.6M-fold gap) + MD Anderson Cancer Center Houston TX (clinical administration; EHS Insight no OEL) [3 pts]; FIRST CLDN18.2 ANTIBODY EVER + FIRST CLAUDIN FAMILY ANTIBODY EVER [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_zolbetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan zolbetuximab with CLDN18.2 claudin IgG1 mAb bypass context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1449236-65-6"
                "reading_ugm3": reading_ugm3,
                "context": "cldn18_2_first_claudin_family_antibody_88th_class_bla761286"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, igg1_biologic_bypass_flag,
    #                    cldn18_2_target_novel_flag, claudin_family_first_flag,
    #                    spotlight_os_hr, glow_os_hr, adcc_cdc_mechanism,
    #                    h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_zolbetuximab("1449236-65-6", 0.00035))
    print(r)
    # {'hd_category': 1, 'igg1_biologic_bypass_flag': True,
    #  'cldn18_2_target_novel_flag': True, 'claudin_family_first_flag': True,
    #  'spotlight_os_hr': 0.75, 'glow_os_hr': 0.77,
    #  'adcc_cdc_mechanism': True, 'h360_flag': True, 'threshold': 22}

Attack #669. Blog #166. 88th mechanism class. Glyphward — See what text-only scanners miss.